<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521167</url>
  </required_header>
  <id_info>
    <org_study_id>MAvsTOBA</org_study_id>
    <nct_id>NCT03521167</nct_id>
  </id_info>
  <brief_title>Multimodal Analgesia Versus Traditional Opiate Based Analgesia</brief_title>
  <official_title>Multimodal Analgesia Versus Traditional Opiate Based Analgesia and Cardiac Surgery Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain after cardiac surgery can be moderate to severe with incisions to the sternum and lower
      extremities, and also the placement of chest tubes. Postoperative pain may contribute to
      delirium, stress, myocardial oxygen demand supply imbalance, etc. Traditionally postoperative
      pain management after cardiac surgery has been based on opiate analgesics. However, opiates
      have many deleterious side effects including nausea/vomiting, ileus, bladder dysfunction, and
      respiratory depression, which substantially influence patient recovery and may delay
      discharge after surgery.

      The current study is designed to evaluate if an opiate sparing multimodal regimen of tylenol,
      gabapentin, ketamine, lidocaine and dexmedetomidine provided better analgesic effect (pain
      score, postoperative PCA opioid dose), less side effects (PONV) and improved cardiac surgery
      outcome (delirium, a-fib, AKI, dysglycemia) compared to a traditional fentanyl and
      hydromorphine regimen after cardiac surgery. Additionally, it aims to investigate if the
      benefit of multimodal regimen is achieved by combination of all drugs or all drugs except
      dexmedetomodine by introducing third group of study patients who will be randomized to all
      interventions except saline placebo instead of dexmedetomodine infusion.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of analgesic effect</measure>
    <time_frame>Within 3 months after surgery</time_frame>
    <description>Evaluation of analgesic effect by Visual Analogue Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional opioid consumption</measure>
    <time_frame>Within 3 days after operation</time_frame>
    <description>assessed by daily sufentanil PCIA dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative delirium</measure>
    <time_frame>Within 3 days after operation</time_frame>
    <description>evaluated by CAM-ICU criteria</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>traditional opioid based regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>multimodal group with dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>multimodal with saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction.
Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg.</description>
    <arm_group_label>MD</arm_group_label>
    <arm_group_label>M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.</description>
    <arm_group_label>MD</arm_group_label>
    <arm_group_label>M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.</description>
    <arm_group_label>MD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for &gt;65y or if patient having significant sedation/dizziness</description>
    <arm_group_label>MD</arm_group_label>
    <arm_group_label>M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tylenol</intervention_name>
    <description>Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if &lt;70kg</description>
    <arm_group_label>MD</arm_group_label>
    <arm_group_label>M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin Pill</intervention_name>
    <description>Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients &gt;65y or with GFR &lt; 50 Consider dose reduction in patients with sleep apnea</description>
    <arm_group_label>MD</arm_group_label>
    <arm_group_label>M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tylenol Pill</intervention_name>
    <description>Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if &lt;70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)</description>
    <arm_group_label>MD</arm_group_label>
    <arm_group_label>M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA II-III Grade

          -  BMI 18-31kg/m2

          -  Adult patients presenting for on-pump cardiac surgery through median sternotomy

        Exclusion Criteria:

          -  Cardiac surgery without sternotomy

          -  emergency surgery

          -  h/o allergy to any of the medications in the research protocol

          -  hepatic disease with elevated liver enzymes (preoperative SGPT and SGOT elevated to
             1.5 times maximum normal value)

          -  pregnancy

          -  unable to give consent

          -  preoperative mental disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Jin, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kefang Guo, PHD</last_name>
    <phone>+86-13817706936</phone>
    <email>drguokefang@foxmail.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

